Ankylosing Spondylitis and axial spondyloarthritis (non-radiographic) - adalimumab, etanercept infliximab and golimumab (inc rev TA143 and TA233) [ID694]
Notice of Appeal
NICE has received 1 appeal against the Final Appraisal Determination on the above technology from the following organisations:
- Merck Sharp Dohme (MSD)
The appeal hearing due to be held on 24 November 2015 has been cancelled as the appellants withdrew their appeal.
This page was last updated: